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Shrinkage estimation for dose-response modeling in phase II trials
with multiple schedules
Burak Kürsad Günhan,1 2 Paul Meyvisch,3 Tim Friede1
Recently, phase II trials with multiple schedules (frequency of administrations) have become more
popular, for instance in the development of treatments for atopic dermatitis. If the relationship of
the dose and response is described by a parametric model, a simplistic approach is to pool doses
from different schedules. However, this approach ignores the potential heterogeneity in dose-response
curves between schedules. A more reasonable approach is the partial pooling, i.e. certain param-
eters of the dose-response curves are shared, while others are allowed to vary. Rather than using
schedule-specific fixed-effects, we propose a Bayesian hierarchical model with random-effects to model
the between-schedule heterogeneity with regard to certain parameters. Schedule-specific dose-response
relationships can then be estimated using shrinkage estimation. Considering Emax models, the pro-
posed method displayed desirable performance in terms of the mean absolute error and the coverage
probabilities for the dose-response curve compared to the complete pooling. Furthermore, it outper-
formed the partial pooling with schedule-specific fixed-effects by producing lower mean absolute error
and shorter credible intervals. The methods are illustrated using simulations and a phase II trial
example in atopic dermatitis. A publicly available R package, ModStan, is developed to automate the
implementation of the proposed method (https://github.com/gunhanb/ModStan).
Keywords: Shrinkage estimation, multiple schedules, Bayesian inference, phase II trials.
1 Introduction
In phase II of any clinical development program, the investigations of the dose-response relationship
of a compound is crucial. Usually, there are two main goals of these investigations: (a) establishing a
dose-response signal and (b) estimating the dose-response function (Ruberg, 1995). In addition to the
dose, a treatment plan of a phase II trial includes the schedule (or dose regimen), that is the frequency of
the administration, for instance a weekly or biweekly schedule. Recently, phase II trials with multiple
schedules have become more popular, for instance in the development of monoclonal antibodies as
treatments for a variety of diseases including hypercholesterolaemia (Giugliano et al., 2012) and atopic
dermatitis (Thaçi et al., 2016). Eichenfield and Stein Gold (2017) reviewed many therapies for atopic
dermatitis which were in phase II or III of clinical development. Multiple schedules were investigated
in phase II trials of almost half of the investigated therapies (Eichenfield and Stein Gold, 2017).
However, standard methods for dose-response estimation cannot account for multiple schedules.
Estimating separate dose-response curves for each schedule by a parametric model is a one way
to tackle this problem, that is full stratification of the dose-response curves. However, this method
ignores the information shared between different schedules. Alternatively, one can completely pool
doses from different schedules. The main problem with complete pooling is that it does not take into
account the potential heterogeneity between different schedules. A more reasonable approach is the
partial pooling, that is certain parameters of the dose-response curves are shared, while others are
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allowed to vary. A placebo effect parameter can be, reasonably, assumed shared between schedules,
whereas this may not be true for the ED50 parameter, the dose at which half of the maximum effect
is reached. Feller et al. (2017) proposed a partial pooling approach in which unshared parameters are
treated as schedule-specific fixed-effects (Möllenhoff et al., 2019).
We consider trials with (very) few schedules of small to moderate size. Here, borrowing available
information is of great interest. Rather than using schedule-specific fixed-effects, we propose a Bayesian
hierarchical model with random-effects to model the between-schedule heterogeneity with regard to
certain parameters. schedule-specific parameters can be estimated using shrinkage estimation. The
basic idea of the shrinkage estimation is that stratified parameter estimates can be improved by
shrinking towards the population mean. It has been shown that the shrinkage estimation improves the
estimation accuracy in comparison to estimates obtained by pooling or stratification (Efron and Morris,
1975). Shrinkage estimation in the context of clinical trials were investigated by Jones et al. (2011) and
Freidlin and Korn (2013) among others. A popular application is the estimation of the treatment effect
in the presence of subgroups, for example estimating response rate in a phase II trial with multiple
patient populations (Neuenschwander et al., 2016). Here, we are interested in parametric dose-response
models in the presence of multiple schedules, hence shrinkage estimators of the parameters of a dose-
response model, for example the ED50 parameter of an Emax model. Shrinkage estimation allows
dynamic borrowing (Viele et al., 2014), in which the weights for each schedule depend on the data
instead of using fixed weights. Dynamic borrowing results in considerable gain in efficiency, while being
a robust method against the heterogeneity between schedules. A theoretical justification for shrinkage
can be established through the concept of exchangeability of the parameters between schedules. This
means that finding no systematic reason to distinguish schedule-specific parameters, in other words,
they are similar, but not identical (Greenland, 2000). Usually, the assumption of exchangebility
indicates the schedule-specific parameters come from a common distribution with an overall mean.
For the ED50 parameter, we assume the re-scaled and log transformed ED50 parameter estimates
(using the corresponding frequency of each schedule) are exchangeable.
In this manuscript, we propose a Bayesian hierarchical model which utilizes shrinkage estimation
for certain parameters of the dose-response model in order to dynamically borrow strength across
schedules in a phase II trial. Another contribution is the introduction of a publicly available R
package, ModStan. In Section 2, two phase II trials with multiple schedules for the treatment of atopic
dermatitis are described. We introduce the proposed method to analyze phase II trials with multiple
schedules in Section 3. We also describe partial pooling with assuming schedule-specific fixed-effects
for certain parameters, discuss the choice of priors and implementation of the proposed method. We
evaluated the long-run properties of different methods in a simulation study in Section 4. One of the
illustrative applications is revisited to display the proposed method and compare it to the alternatives
in Section 5. We close with some conclusions and outlook.
2 Illustrative applications
Atopic dermatitis, the most common form of eczema, is a chronic inflammatory disease that is char-
acterized by skin rash and itching (Mayo Clinic, 2018). Recently, there is an increasing number
of clinical trials investigating novel systemic agents for the treatment of atopic dermatitis (Alexan-
der et al., 2019). We consider phase II trials of two human monoclonal antibodies, dupilumab and
MOR106, for the treatment of atopic dermatitis. Designs of two trials are listed in Table 1. For both
trials, patients were randomized into six arms including a placebo arm. We consider these two trials,
since they were both designed to investigate multiple schedules. The dupilumab trial contains three
schedules (weekly, biweekly, and monthly), whereas the MOR106 trial contains two (biweekly and
2
monthly). The placebo doses were administered with the highest frequencies including a weekly and
a biweekly schedule for dupilumab and MOR106, respectively. The primary endpoint of both trials
is the percentage change from baseline in Eczema Area and Severity Index (EASI) score at Day 85.
The EASI scoring system is used to grade the severity of the signs of eczema. EASI scores take values
between 0 and 72 and higher EASI score means higher severity. Dupilumab and MOR106 trials are
used to motivate our simulation studies in Section 4. The dupilumab trial was completed in September
2014. Multiple comparisons procedure was used as the primary statistical analysis in the dupilumab
trial (Thaçi et al., 2016). For the purpose of illustration, we will analyze the dupilumab trial using
different modeling approaches in Section 5. In October 2019, the MOR106 trial was terminated due
to lack of efficacy in the interim analysis (MorphoSys AG, 2019).
Table 1: Designs of two phase II trials in atopic dermatitis (Dupilumab and MOR106) involving
different schedules. Clinicaltrial.gov identifiers are displayed for two trials.
Dupilumab: NCT01859988 MOR106: NCT03568071
Arm Schedule Dose Planned Schedule Dose Planned
(mg/m2) sample size (mg/kg) sample size
1 Weekly 0 40 Biweekly 0 45
2 Weekly 300 40 Biweekly 1 45
3 Biweekly 200 40 Biweekly 3 45
4 Biweekly 300 40 Biweekly 10 45
5 Monthly 100 40 Monthly 1 30
6 Monthly 300 40 Monthly 3 30
3 Statistical methods
Assume that a response yijk (an efficacy or a safety outcome) is observed for schedule i, dose j and
patient k. Following Feller et al. (2017), we assume a normal likelihood for a continuous outcome:
yijk ∼ N (f(d(i)j ,θ), σ2i ) (1)
where θ refers to the model parameters and σi to the error standard deviation. The f(d(i)j ,θ) represents
the functional form of the dose-response relationship for schedule i. Other outcome types, for instance
dichotomous or count, can be modeled by specifying appropriate likelihood (e. g. Binomial or Poisson)
and the link function (e. g. logit or log transformation).
There are a number of candidate models for the functional form including the popular Emax model
(Thomas et al., 2014), that is
f(d(i)j ,θ) = E
(i)
0 + E(i)max
d
(i)
j
ED(i)50 + d
(i)
j
(2)
where E(i)0 is the placebo response and E(i)max is the maximum effect attributable to the drug. The ED
(i)
50
parameter represents the dose at which half of the maximum effect is reached. In the manuscript, we
exclusively use the Emax model, see Bretz et al. (2005) for different candidate models.
As explained in the introduction, one way of modeling the dose-response curves is to treat all
model parameters as schedule-specific fixed-effects. However, such an analysis is not the most efficient,
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when certain aspects of the dose-response curves in different schedules are similar. Alternatively, one
can consider a complete pooled analysis in which all model parameters from different schedules are
assumed to be the same. This approach is also problematic, since it ignores the potential heterogeneity
between dose-response curves of different schedules. A more reasonable approach is the partial pooling
(Feller et al., 2017), which strikes a balance between efficiency and robustness. It is often reasonable
to assume that placebo effect E(i)0 is the same for different schedules, that is, E
(1)
0 = E
(2)
0 = . . . .
This is especially the case, when there is only one placebo arm investigated in the trial as in the
illustrative trials described in Section 2. In some situations, it might also make sense to assume that
the maximum efficacy for high doses is same, E(1)max = E(2)max = . . . . However, it might not be reasonable
to assume the dose providing half of the maximum efficacy is the same for different schedules, that
is ED(1)50 6= ED(2)50 6= . . . . Feller et al. (2017) suggested to treat the unshared parameters, for example
E(i)max and/or ED
(i)
50 , as schedule-specific fixed-effects in the partial pooling approach.
3.1 Proposed method: Partial pooling with random-effects
Rather than using schedule-specific fixed-effects, we propose a Bayesian hierarchical model with
random-effects to model the between-schedule heterogeneity with regard to certain parameters in
the partial pooling approach. In other words, we suggest partial pooling with assuming schedule-
specific random-effects for certain parameters of the dose-response model. To be concrete, assume
that we want to obtain schedule-specific random-effects for ED(i)50 . Firstly, we need to re-scale ED
(i)
50
parameters. For this reason, we specify a reference schedule (iref). The re-scaled parameters are given
by ED∗(i)50 = ED
(i)
50 (f (i)/f (iref)) where f (iref) and f (i) are the frequency of administration of the ref-
erence schedule iref and the schedule i, respectively. The ED(i)50 is modeled on the log-scale, since it
is necessarily positive as a dose. We assume that the re-scaled schedule-specific ED∗(i)50 estimates are
exchangeable
log(ED∗(i)50 ) ∼ N (µED50 , τ2ED50) (3)
where µED50 is the overall mean and τED50 is the between-schedule heterogeneity in log(ED
∗(i)
50 ). Our
main interest is in the schedule-specific estimates, ED(i)50 . If the heterogeneity τED50 is zero, then the
model reduces to a model assuming shared ED∗(i)50 parameters. Note that the results are invariant to
the choice of the reference schedule. Furthermore, similar to the ED50 parameter, shrinkage estimates
of Emax parameter can be obtained. There is no need to use the re-scaling or the log transformation for
the Emax parameter. Treating Emax and/or ED50 parameters differently, assuming either one or both
of them shared between schedules or assuming schedule-specific random-effects, results in a variety of
alternative models.
Complete pooling and partial pooling approaches can be fitted using likelihood estimation. For
example, Möllenhoff et al. (2019) demonstrated the likelihood implementation of the partial pooling
with assuming schedule-specific fixed-effects for ED(i)50 using constrained nonlinear optimization via
alabama (Varadhan, 2015) R package. Alternatively, Bayesian approaches can be used, which we
consider in this paper.
3.2 Prior distributions
For the Bayesian implementation, we need to specify prior distributions for the model parameters
E0, Emax µED50 , τED50 and σ for the partial pooling assuming schedule-specific random-effects for
ED(i)50 . We use vague (non-informative) priors, N (0, 1002), for the parameters E0 and Emax, and
a half-normal prior with scale 100 for σ, HN (100). The parameters µED50 and τED50 need special
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attention, since the priors of both parameters have strong influence on the posterior estimates. The
difficulty of the estimation of the τED50 stems from the small number of the schedules. For example,
in our two illustrative trials, there are only two and three schedules available. This is similar to the
meta-analysis of few studies, in which the estimation of the between-trial heterogeneity has gained
considerable attention in the literature (Gelman, 2006). Friede et al. (2017) suggested the use of weakly
informative priors (WIP) for the heterogeneity parameter in the case of meta-analysis of few studies,
specifically half-normal priors with the scale of 0.5 or 1, when relative measures such as odds ratios,
relative risks or hazard ratios (on the logarithmic scale) are used to describe the effect. Inspired
by these, we can also construct a WIP for the τED50 to represent plausible range of ED
∗(i)
50 values
(Spiegelhalter et al., 2004). The 95% of values of log(ED∗(i)50 ) will lie in the interval µED50±1.96 ·τED50 ,
hence the 97.5% and 2.5% values of log(ED∗(i)50 ) are 2 · 1.96 · τED50 apart. Accordingly, the ratio of
the 97.5% to the 2.5% point of the distribution of ED∗(i)50 values is exp(3.92 · τED50). Table 2 lists the
“range” of ED∗(i)50 values based on different τED50 . In order to cover typical τED50 values conservatively,
we will use half-normal priors with scale 1, i.e. HN (1). When we are interested in the shrinkage
estimates of Emax, the construction of the WIP for τEmax is slightly different. This is because Emax
is computed on the original scale, not on the logarithmic scale. Here, the difference (instead of the
ratio) between the 97.5% and the 2.5% point of the distribution of Emax values is 3.92 · τEmax. To
cover plausible τEmax values, we will use half-normal priors with the scale 10, HN (10).
Table 2: Between-schedule heterogeneity τED50 in log(ED
∗(i)
50 ): τED50 referring small to very
large heterogeneity. The “range”, exp(3.92 · τED50), refers to the ratio of the 97.5% to the
2.5% point of the distribution of ED∗(i)50 .
τED50 “range” of ED
∗(i)
50
0.125 (small) 1.63
0.25 (moderate) 2.66
0.5 (substantial) 7.10
1 (large) 50.40
2 (very large) 2540.20
The parameter ED50 is different from E0 and Emax in the sense that it is the only parameter that
enters the model non-linearly. In the frequentist framework, it is a common practice to impose bounds
(lower and upper bounds) on the space for ED50, since the maximum likelihood estimator (MLE)
often does not converge (Bornkamp, 2014). However, the estimate will often exactly equal to the
specified upper bound, which is unacceptable. In a Bayesian framework, simple prior choice for the
ED50 are uniform distributions with finite bounds. However, uniform prior distributions on ED50 are
problematic, since they strongly depend on the parametrization: One may end up with completely
different implied prior distributions for the dose-response curve. A better prior for ED50 is the Jeffreys
prior, which is invariant to parametrization. It is defined as p(θ) ∝ √|I(d,w,θ)| where √|I(d,w,θ)|
is the Fisher information, and w is the vector of proportion of patients allocated at dose d. Hence,
Jeffreys prior depends on the observed design (x,w). One cannot state the Jeffreys prior before data
collection, which is crucial in many applications, e.g. in the presence of missing data or two stage
designs.
Bornkamp (2012) introduced the functional uniform prior which is a modified version of the Jef-
freys prior. Functional uniform priors are uniformly distributed on the potential different shapes of the
underlying nonlinear model function. These priors are also invariant with respect to parametrization
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of the model function and typically result in rather non-uniform prior distributions on the parameter
scale. Instead of the actual observed design, functional uniform priors are calculated using a grid of
doses as x and equal weights for w. More specifically, say, the gradient function of the Emax model
is given by Jx(θ) = (1, x/(x + ED50),−x/Emax/(x + ED50)2). Let x be a grid of doses and F (θ) be
the matrix with Jx(θ), x in the rows. Then, the functional uniform prior is proportional to
√|Z∗(θ)|
where Z∗(θ) = F T (θ)F (θ) (see Bornkamp (2014) for more detailed explanations). An approxima-
tion of the functional uniform prior for ED50 is given as the log-normal distribution with mean -2.5
and standard deviation 1.8, when the ED50 is re-scaled with the maximum available dose D, that is
ED50/D (Bornkamp, 2014). For the simulations and the application, we used the approximation of
the functional uniform prior, since it is computationally cheaper. In all models, we use the bounds [0,
1.5 ·D] for the space of ED50 (or µED50) parameter.
3.3 Implementation of the proposed method
In a Bayesian framework, we fitted the described statistical models using the probabilistic program-
ming language Stan which employs a modern Markov chain Monte Carlo (MCMC) algorithm, namely,
Hamiltonian Monte Carlo with the No-U-Turn Sampler (Carpenter et al., 2017). The parametrization
used for the statistical model influences the MCMC performance. A centered parametrization such as
Equation (3) may cause some computational difficulties such as difficulty in convergence in the presence
of data sparsity such as meta-analysis of few studies (Betancourt and Girolami, 2015) or dose-response
modeling of phase II trials with few schedules. An alternative parametrization, that is a non-centered
parametrization, overcomes these computational difficulties. To be more precise, by the reparametriza-
tion of the location and scale parameters, Equation (3) becomes log(ED∗(i)50 ) = µED50 +ui ·τED50 where
ui ∼ (0, 1) (Günhan et al., 2020). The Stan code defining the partial pooling with schedule-specific
random-effects for ED(i)50 is shown in Listing 1.
To facilitate the implementation of our proposed method for the practitioners, we have developed an
R package, ModStan (https://github.com/gunhanb/ModStan). ModStan is a purpose-build package
defined on top of the rstan, the R interface for Stan. We show how to install and use ModStan in
Appendix A.
4 Simulation study
In order to evaluate the long-run properties of the proposed method and compare it with some alter-
native methods, a simulation study was conducted.
4.1 Simulation settings and implementation
The scenarios considered are motivated by the dupilumab and MOR106 trials described in Section 2.
Each generated trial consists of seven arms: one placebo arm and 1, 3, and 10 mg/kg for both biweekly
and monthly schedules. The primary outcome is the percentage change from baseline in EASI score.
Hence, the datasets are generated under the assumption of normally distributed outcomes, specifically
Equation (1). The underlying dose-response function is assumed to be an Emax model, that is
Equation (2). True values for E(i)0 , E(i)max and σi are taken as −20%, −60%, and 35% for both schedules,
respectively. Furthermore, EDbiweekly50 is assumed to be 2 mg/kg. A total of 27 scenarios are obtained
by varying the EDmonthly50 (ED
monthly
50 ∈ {1, 2, 3, 3.5, 4, 4.5, 5, 6, 10 (mg/kg)}) and sample sizes of each
arm (N ∈ {30, 45, 60}). EDmonthly50 values are chosen to investigate the influence of the difference
between true values of EDbiweekly50 and ED
monthly
50 on the performance. Figure 1 displays different dose-
response curves for the monthly schedule investigated in the simulations. When EDmonthly50 corresponds
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12 data {
3 int<lower=1> N_obs; // num of observations
4 int<lower=1> N_schedule; // num of schedules
5 int<lower=1> N_pred; // num of predicted doses
6 real resp[N_obs]; // responses
7 real<lower=0> dose[N_obs]; // doses
8 int schedule[N_obs]; // schedule indicator
9 real<lower=0> freq[N_obs]; // frequency of administration (hrs)
10 }
11 parameters {
12 real E0; // placebo effect (shared)
13 real Emax; // Emax parameter (shared)
14 real log_ED50_raw[N_schedule]; // re-scaled log(ED50) parameters
15 real<lower=0> sigma; // standard deviation for errors
16 real<lower=0, upper=1.5> mu_ED50_raw; // mean of log(ED50) random-effects
17 real<lower=0> tau_ED50; // between-schedule heterogeneity
18 }
19 transformed parameters{
20 real mu_ED50;
21 real log_ED50[N_schedule];
22 real<lower=0> ED50[N_schedule];
23 vector[N_obs] resp_hat;
24
25 mu_ED50 = log(mu_ED50_raw * max(dose));
26 for(i in 1:N_schedule)
27 log_ED50[i] = mu_ED50 + log_ED50_raw[i] * tau_ED50;
28 // Taking exponentials and rescaling ED50 parameters
29 for(i in 1:N_schedule)
30 ED50[i] = exp(log_ED50[i]) * (freq[i]/ freq_ref);
31
32 // Dose-response: Emax model
33 for(i in 1:N_obs)
34 resp_hat[i] = E0 + (Emax * dose[i]) / (ED50[schedule[i]] + dose[i]);
35 }
36 model {
37 // random-effects
38 log_ED50_raw ~ normal(0, 1); // implies log(ED50) ~ normal(mu_ED50, tau_ED50)
39 // likelihood
40 resp ~ normal(resp_hat, sigma);
41 // prior distributions
42 sigma ~ normal(0, 100);
43 E0 ~ normal(0, 100);
44 Emax ~ normal(0, 100);
45 // approximation to the functional uniform prior
46 mu_ED50_raw ~ lognormal(-2.5, 1.8);
47 tau_ED50 ~ normal(0, 1);
48 }
Listing 1: Stan code defining the partial pooling with schedule-specific random-effects for ED50
parameter. The parameters E0, Emax and σ are assumed to be shared between schedules.
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to 4 mg/kg, there is no heterogeneity in ED50 parameters between schedules. This is because if we
re-scale EDmonthly50 to transform on the biweekly scale (simply dividing by two), we obtain 2 mg/kg,
which is the true value of EDbiweekly50 . Accordingly, when the true value of ED
monthly
50 deviates from 4
mg/kg, the heterogeneity between schedules in ED50 increases. The simulations were carried out with
1 000 replications per scenario.
Figure 1: Dose-response curves for the monthly schedule investigated in the simulation study.
Different curves are generated by varying EDmonthly50 parameter value.
In the proposed method, we assume that E(i)0 , E(i)max and σi are shared between schedules, while
ED(i)50 are assumed to be schedule-specific random-effects. In other words, the proposed method
corresponds to the partial pooling with assuming schedule-specific random-effects for ED(i)50 (“PP -
RE”). As a comparator, we use the model in which ED(i)50 are assumed to be schedule-specific fixed-
effects, while other parameters are shared (“PP - FE”). Both partial pooling approaches (PP - RE
and PP - FE) are fitted via a Bayesian approach. We also consider the complete pooling method via
a frequentist and a Bayesian approach (“CP (Frequentist)” and “CP (Bayesian)”). For the partial
pooling with schedule-specific random-effects, we used the biweekly schedule as the reference schedule
to re-scale the ED(i)50 parameters. To implement the complete pooling approaches, all doses should be
re-scaled into the same schedule. For this purpose, we transform the doses from the monthly schedule
into the biweekly schedule. Accordingly, the new set of doses becomes {0, 0.5, 1, 1.5, 3, 10 (mg/kg)}
for complete pooling approaches.
The complete pooling (Frequentist) is fitted using fitMod function from the DoseFinding (Bornkamp
et al., 2018) R package. All Bayesian methods are fitted using Stan and the prior distributions from
Section 3.2 are used. Three MCMC chains were run in parallel for a total of 4 000 iterations including
2 000 iterations of burn-in. Convergence diagnostics are evaluated in some replications, these MCMC
settings are chosen accordingly. The ED50 parameter is assumed to be within the bounds of [0.001,
1.5 · 10] to ensure identifiability for all methods.
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4.2 Simulation results
For each simulation run, we calculated point estimates (fˆ) for the dose-response function (f) (the
pointwise posterior median or the maximum likelihood estimate) at some pre-specified dose levels.
For this purpose, ten dose levels are chosen between 0 and 10 mg/kg equidistantly, namely dosel ∈
{0.00, 1.11, . . . , 10.00}. Additionally, interval estimates (95% confidence interval or 95% equi-tailed
credible intervals) are derived at each dosel. These computations are done for the dose-response
function of the biweekly schedule. The following three performance measures are calculated:
• MAE: Mean absolute error for the dose-response function, 1/10 Σ10dosel=0|f(dosel)− fˆ(dosel)| at
each dosel.
• Coverage probability: Mean coverage probability of the interval estimates evaluated at each
dosel.
• Mean length: Mean length of the interval estimates at each dosel.
The lower MAE for the point estimates, the shorter interval estimates, and the coverage probability
of 95% for the interval estimates are desirable. The MAE obtained by the four methods is displayed
in the first row of Figure 2. Different columns of Figure 2 correspond to different sample sizes N
which are investigated in the simulations. Across different sample sizes, the relative performances of
the four methods remain similar. The scenario of EDmonthly50 = 4 corresponds to the scenario without
heterogeneity in the re-scaled ED(i)50 between biweekly and monthly schedules, which is shown by a
vertical dashed line. The heterogeneity increases, when EDmonthly50 deviates from 4. Both complete
pooling approaches display better performance than both partial pooling approaches in terms of
the MAE, when the EDmonthly50 is 4. However, the partial pooling approaches result in more robust
performance across EDmonthly50 values in comparison to the pooling approaches. The partial pooling
with random-effects uses the prior HN (1) for the heterogeneity parameter τED50 . If we increase
the value of the prior standard deviation (that is 1), then the performance of the partial pooling
with random-effects will get closer to the partial pooling with fixed-effects. Similarly, if we assume
that τED50 equals to zero, the partial pooling with random-effects reduces to, effectively, the complete
pooling (Bayesian). The partial pooling with random-effects yields better performance than the partial
pooling with fixed-effects in terms of the MAE across different EDmonthly50 values and sample sizes except
the most extreme scenarios, namely EDmonthly50 = 1 or 10. Note that the main difference between the
complete pooling (Bayesian) and complete pooling (Frequentist) is that in the former, functional
uniform priors used for ED(i)50 parameters. The small discrepancy between the MAE obtained by
the complete pooling (Bayesian) and the complete pooling (Frequentist) can be explained by this
difference. Furthermore, when the sample sizes increase, the MAE decreases in the four methods as
expected.
Figure 2 also shows coverage probabilities of the interval estimates obtained by the four methods.
The complete pooling approaches result in a concave shape and display unacceptably low coverage
when EDmonthly50 deviates from 4. This undesirable performance of the complete pooling approaches is
more pronounced, when the sample size increases. As in the MAE, both partial pooling approaches
show more robust performance in terms of the coverage probabilities in comparison to the complete
pooling approaches. The partial pooling with random-effects yields superior performance in terms of
the coverage probability compared to the partial pooling with fixed-effects across different EDmonthly50
values and sample sizes except when EDmonthly50 = 1. Figure 3 illustrates the ratios of lengths of credible
intervals for the dose-response functions obtained by the partial pooling approaches. The denominator
of the ratio is the length of the credible interval obtained by the partial pooling with random-effects.
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The partial pooling with random-effects results in slightly shorter credible intervals, while it produces
slightly higher coverage probability compared to the partial pooling with fixed-effects in most of the
scenarios.
To examine the influence of the potential heterogeneity in E(i)max between schedules, we conducted
additional simulations. True values for E(i)0 and σi are taken as -20% and 35% for both schedules,
respectively. The EDbiweekly50 and ED
monthly
50 are assumed to be 2 and 4 mg/kg, respectively. This
corresponds to assuming no heterogeneity in ED(i)50 parameters between schedules, since we focused on
E(i)max in these simulations. The Ebiweeklymax is assumed to be -60%. Sample size for each arm is 45. Three
scenarios are generated by varying Emonthlymax values (Emonthlymax ∈ {−70%,−60%,−50%}). Notice that
when Emonthlymax = −60%, there is no heterogeneity in E(i)max values. In the partial pooling with fixed-
effects, both E(i)max and ED
(i)
50 parameters are treated as schedule-specific fixed-effects. In the partial
pooling with random-effects, both parameters E(i)max and ED
(i)
50 are assumed to be schedule-specific
random-effects. The simulation results are listed in Table 3. In the scenario of Emonthlymax = −60%, the
complete pooling approaches result in lower MAE in comparison to the partial pooling approaches,
while reaching the coverage probability of 95% for the confidence intervals. However, in other scenarios,
complete pooling approaches yield worse performance in terms of the MAE and coverage probabilities
compared to the partial pooling approaches. The partial pooling with random-effects results in smaller
MAE and the shorter credible intervals compared to the partial pooling with fixed-effects in all three
scenarios.
When we take into account all simulation results, the partial pooling approaches are more robust
in terms of the MAE and the coverage probabilities across scenarios compared to the complete pooling
approaches. The partial pooling with random-effects yields better performance than the partial pooling
with fixed-effects in terms of the MAE and the mean length of the credible intervals with the exception
of highly heterogeneous scenarios.
5 Revisiting the Dupilumab trial
We return to the dupilumab trial which was described in Section 2. The least square means and
standard errors for different arms of the trial are listed in Table 4 as reported in Thaçi et al. (2016).
In total, 379 patients completed the trial. We analyzed the dataset assuming normal distribution for
least square means with the given standard errors. Note that this is different than assuming normality
for the observations as described in Equation (1) as reported in the reference paper for convenience
(Thaçi et al., 2016). This will show that the proposed method also works with weaker assumption,
as we only use an arm-level data instead of an observation-level data. Five different models were
fitted in a Bayesian framework. We compare them via the approximate leave-one-out cross-validation
information criteria (LOO-IC) (Vehtari et al., 2017). Note that LOO-IC has the same purpose as the
Akaike Information Criteria (AIC) used in the frequentist framework and similar to the AIC, the lower
value indicates the better model. All models assume an Emax model for the dose-response relationship.
We use prior distributions described in Section 3.2. The model descriptions are listed in Table 5. Model
1 corresponds to the complete pooling. In Models 2-5, the E(i)0 are assumed to be shared between
schedules, while ED(i)50 and E(i)max are treated differently in each model. Hence, Models 2-5 are partial
pooling approaches. In Models 2 and 3, E(i)max are assumed to be shared between schedules. Model 2
assumes schedule-specific fixed-effects for ED(i)50 , while Model 3 uses schedule-specific random-effects
for ED(i)50 . Model 4 assumes schedule-specific fixed-effects both for ED
(i)
50 and E(i)max, whereas Model 5
uses schedule-specific random-effects both for ED(i)50 and E(i)max. For the complete pooling, the doses
are transformed into the biweekly scale, thus the new set of doses are {0, 50, 150, 200, 300, 600}. For
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Table 3: Simulation results for varying Emonthlymax scenarios. The mean absolute error (MAE) for
the dose-response function, coverage probabilities and mean length of the interval estimates
for the dose-response function obtained by the four methods. Four methods include complete
pooling approaches using frequentist, CP (Frequentist), and Bayesian methods, CP (Bayesian),
and partial pooling approaches using schedule-specific fixed-effects (PP - FE) and schedule-
specific random-effects (PP - RE) for ED(i)50 .
Emonthlymax
-60% -70% -50%
Mean absolute error
CP (Frequentist) 1.63 2.44 2.51
CP (Bayesian) 1.62 2.23 2.87
PP - FE 2.04 2.03 2.03
PP - RE 1.88 1.90 2.02
Coverage probability
CP (Frequentist) 0.95 0.87 0.84
CP (Bayesian) 0.95 0.87 0.84
PP - FE 0.96 0.96 0.96
PP - RE 0.96 0.96 0.95
Mean length
CP (Frequentist) 5.78 5.77 5.82
CP (Bayesian) 5.53 5.48 5.47
PP - FE 6.96 6.96 6.95
PP - RE 6.59 6.64 6.71
Models 3 and 5, we use the biweekly schedule as the reference schedule.
Table 5 displays the LOO-IC values for the five models. The complete pooling results in the
best model in terms of the LOO-IC. The second and third best models are the partial pooling with
schedule-specific random-effects for ED(i)50 and the partial pooling with schedule-specific fixed-effects
for ED(i)50 , respectively. Apparently, the model complexity is heavily penalized by LOO-IC for this
dataset, hence LOO-IC results in lower values for the simpler models. One possible reason is the data
sparsity, numbers of dose levels available for different schedules are 2, 3, and 3 (by including placebo
arm for all schedules). Based on these results, hereafter, we focus on Models 1-3.
The posterior estimates obtained by Model 1 (Complete Pooling), Model 2 (PP - FE), and Model
3 (PP - RE) are shown in Table 6. Recall that for Models 2 and 3, the Emax parameters are shared
between schedules. The estimates EDweekly50 and ED
monthly
50 of the complete pooling are calculated by
re-scaling the estimate of EDbiweekly50 . Across three methods, estimates of E0 are quite similar. For
Emax and ED(i)50 , however, the partial pooling with fixed-effects yields different results compared to
the complete pooling and the partial pooling with random-effects. The heterogeneity parameter τED50
results in high uncertainty (posterior mean 0.5 with standard deviation of 0.5), indicating the complete
pooling is adequate. The estimated dose-response functions fˆ by the complete pooling, the partial
pooling with fixed-effects, and the partial pooling with random-effects are displayed in Figure 4.
The fˆ(t) are the posterior medians for the dose-response function f(t) evaluated at each i where
i ∈ {0, 20.7, . . . , 600 (mg/m2-biweekly)}, equidistant sequence between 0 and 600 with 30 elements.
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Table 4: The dupilumab trial: Sample sizes, least square (LS) means, and standard errors for
each arm in the trial.
Arm Schedule Dose (mg/m2) Sample size LS mean Standard error
1 Weekly 0 61 -18.1 5.2
2 Weekly 300 63 -73.7 5.2
3 Biweekly 200 61 -65.4 5.2
4 Biweekly 300 64 -68.2 5.1
5 Monthly 100 65 -44.8 5.0
6 Monthly 300 65 -63.5 4.9
Table 5: Analyzing the dupilumab trial: The approximate leave-one-out information criterion
(LOO-IC) obtained by five different models. In all models, E(i)0 are assumed to be shared be-
tween schedules. The first model is the complete pooling, thus effectively all model parameters
are assumed to be shared.
Model ED(i)50 E(i)max LOO-IC
Model 1 Shared Shared 36.0
Model 2 Fixed-effects Shared 39.8
Model 3 Random-effects Shared 37.4
Model 4 Fixed-effects Fixed-effects 41.7
Model 5 Random-effects Random-effects 41.1
Similarly, 95% equi-tailed credible intervals evaluated at each i are displayed in Figure 4. The median
dose-response curve obtained by the complete pooling and the partial pooling with random-effects
are very similar, which is in alignment with the posterior estimates shown in Table 6. The median
dose-response curve estimated by the partial pooling with fixed-effects is slightly different from the
complete pooling and the partial pooling with random-effects. As expected, the complete pooling
produces the shortest 95% credible intervals around fˆ , whereas the partial pooling with fixed-effects
gives the widest. Such behaviour was also observed in the simulations. The dupilumab trial is
similar to the scenarios when the sample size for each arm is 60, and both EDbiweekly50 and ED
monthly
50
do not deviate much from EDbiweekly50 , meaning that low heterogeneity in ED
(i)
50 between schedules.
Additionally, Figure 5 (Appendix B) demonstrates the marginal posterior density estimates of ED(i)50
obtained by three methods alongside with the priors used for ED(i)50 in the partial pooling with fixed-
effects. The posterior and prior distribution for the EDbiweekly50 parameter are very similar in the partial
pooling with fixed-effects. Recall that other than the placebo arm, there is only one arm with weekly
schedule, hence indicating the data sparsity problem. In conclusion, although the complete pooling
may be sufficient for this particular application, we obtain very similar dose-response estimates by
using the partial pooling with random-effects.
6 Conclusions and outlook
An assumption of the homogeneity between schedules can be considered unrealistic, hence a partial
pooling is more reasonable than the complete pooling. Rather than using schedule-specific fixed-effects
in a partial pooling approach, we have proposed to use schedule-specific fixed-effects for the certain
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Table 6: The estimates obtained by analyzing the dupilumab trial. Posterior means and
standard deviations obtained by the complete pooling, the partial pooling with fixed-effects
(PP - FE), and the partial pooling with random-effects (PP - RE) are shown. See the main
text for the descriptions of the methods.
CP PP - FE PP - RE
Mean SD Mean SD Mean SD
E0 -18.5 4.9 -18.1 5.0 -18.2 5.1
Emax -61.0 7.4 -56.9 8.0 -60.0 8.6
EDweekly50 32.3 15.1 20.4 27.0 30.0 29.2
EDbiweekly50 64.6 30.3 37.4 35.3 56.9 40.6
EDmonthly50 129.1 60.6 100.0 46.2 116.7 58.7
τED50 0.5 0.5
parameters such as ED50, allowing dynamically borrowing information in a fully Bayesian framework.
In simulation studies, the proposed method displayed more robust performance in terms of the mean
absolute error and coverage probabilities for the dose-response function f(t) compared to the complete
pooling. Furthermore, the proposed method produces lower mean absolute error and shorter interval
estimates for f(t) across most of the scenarios compared to using schedule-specific fixed-effects in a
partial pooling approach.
In this paper, we focused on the Emax model for the dose-response function. To account for the
model uncertainty, it is important to consider alternative functions, such as log-linear or exponential.
The shrinkage estimation can be applied to such alternative dose-response models, as well. One way
of dealing with the model uncertainty is using a model selection criteria (e.g. AIC in the frequentist
context) to decide the right functional form. Hence, by using a criteria such as LOO-IC, one can utilize
the proposed approach to analyze data from a phase II trial with multiple schedules. Alternatively, a
Bayesian model averaging approach (Schorning et al., 2016) can be used to deal with uncertainty of
dose-response models. Here, we consider phase II trials with multiple schedules. Instead of multiple
schedules, one may investigate phase II trials with multiple subgroups, for example multiple patient
populations. The proposed method is still applicable for such situations.
The parametrization used in the proposed method, Equation (3), can be considered hard to mo-
tivate, since an overall mean of schedule-specific estimates does not have a meaningful interpretation.
This can be overcome by adopting an asymmetric parametrization of schedule-specific estimates in
terms of a reference schedule as follows
ED(k
∗)
50 ∼ N (αED50, 0) (i.e. ED(k
∗)
50 = αED50)
ED(k)50 ∼ N (αED50, β2ED50)
where αED50 and βED50 are the location and scale parameters, respectively (Röver and Friede, 2020).
Although the partial pooling with random-effects is an improvement to complete pooling and the
partial pooling with fixed-effects, the exchangeability assumption bears the risk of too much shrinkage.
Perhaps, it is not very desirable to allow borrowing information for the extreme schedule. To overcome
this, the exchangeability-nonexchangeability (EXNEX) models (Neuenschwander et al., 2016) can be
considered. EXNEX models can be used to share information across similar schedules, while avoid too
much borrowing for the extreme schedule. However, such complicated models should be calibrated
well, due to sparse data available in a typical phase II trial.
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Figure 2: Simulation results for different sample sizes H per arm. The mean absolute error
(MAE) and coverage probabilities for the dose-response curve obtained by four methods with
different sample sizes. Four methods include complete pooling approaches using frequentist,
CP (Frequentist), and Bayesian methods, CP (Bayesian), and partial pooling approaches using
schedule-specific fixed-effects (PP - FE) and schedule-specific random-effects (PP - RE) for
ED(i)50 . The vertical dashed line indicates the scenario without heterogeneity in the re-scaled
ED(i)50 between biweekly and monthly schedules. ED
biweekly
50 is assumed to be 2 mg/kg.
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Figure 3: Simulation results for different sample sizes. Ratios of lengths of credible intervals for
the dose-response curves obtained by the partial pooling with random-effects and the partial
pooling with fixed-effects with different sample sizes. The denominator of the ratio is the length
of credible interval obtained by the partial pooling with random-effects. The vertical dashed
line indicates the scenario without heterogeneity in the re-scaled ED(i)50 between biweekly and
monthly schedules. EDbiweekly50 is assumed to be 2 mg/kg.
Figure 4: Dose-response curve and credible intervals for biweekly schedule obtained by the
complete pooling (CP), the partial pooling with fixed-effects (PP - FE), and the partial pooling
with random-effects (PP - RE) are shown. See the main text for the descriptions of the
methods.
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A How to use the ModStan R package?
The development version of ModStan is available on Github (https://github.com/gunhanb/ModStan)
and can be installed as follows:
library("devtools")
install_github("gunhanb/ModStan")
The dupilumab trial described in the text is available in the package, and it can be loaded as
follows:
library("ModStan")
data("dat.Dupilumab")
See ?dat.Dupilumab for the description of the dataset.
The mod_stan is the main fitting function of the package. The main computations are executed via
the rstan package’s sampling function. We can fit the partial pooling method with schedule-specific
random-effects for the ED(i)50 parameter as follows:
PP.RE.Dupilumab.stan = mod_stan(dose = dose,
resp = resp,
sigma = sigma,
schedule = schedule,
freq = freq,
freq_ref = 24 * 7 * 8,
data = dat.Dupilumab,
model = "PP-RE",
tau_prior_dist = "half-normal",
tau_prior = 1,
chains = 3,
stan_seed = 111,
iter = 4000,
warmup = 2000)
Convergence diagnostics and the results can be very conveniently obtained using the shinystan
package as follows:
library("shinystan")
launch_shinystan(as.shinystan(PP.RE.Dupilumab.stan$fit))
The posterior summary statistics can be obtained using the following command:
PP.RE.Dupilumab.stan
B Marginal posterior density estimates of ED50 (dupilumab trial)
The marginal posterior density estimates obtained by the three methods (CP, PP - FE, PP - RE) are
demonstrated in Figure 5. Also, the prior distribution used for the PP - FE is shown.
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Figure 5: Marginal posterior density estimates of ED50 for weekly, biweekly, and monthly
schedule obtained by the CP, the PP - FE, and the PP - RE. Also, shown is prior distributions
used for the PP - FE.
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